European Healthcare Contract Development and Manufacturing Organization (CDMO) Market 2026-2035
Description
European Healthcare Contract Development and Manufacturing Organization (CDMO) Market Size, Share & Trends Analysis Report by Services (Contract Development and Contract Manufacturing) and Forecast Period 2026-2035
Industry Overview
European CDMO market was valued at $45.6 billion in 2025 and is projected to reach $73.1 billion by 2035, growing at a CAGR of 4.9% during the forecast period (2026–2035). The European healthcare contract development and manufacturing organization market is expanding steadily, supported by rising demand for specialized pharmaceutical outsourcing and advanced biologics production. Increased investment in research-intensive therapies has encouraged pharmaceutical companies to rely on external partners with niche technical expertise. Regulatory harmonization across the region has improved cross-border manufacturing efficiency and reduced time-to-market. Growth is further reinforced by the expansion of small and mid-sized biotech firms seeking flexible development and scale-up capabilities. Technological upgrades in process automation and quality control have strengthened operational reliability. Together, these factors continue to support sustained market expansion over the forecast period.
Market Dynamics
Expansion of Biologics and Advanced Therapies
European CDMOs are increasingly focusing on biologics, cell, and gene therapies, and complex injectables as pharmaceutical pipelines shift toward high-value, specialized treatments. This trend is driven by the need for sophisticated development capabilities, regulatory expertise, and scalable manufacturing infrastructure. Contract manufacturers with proven experience in biologics are gaining preference among innovator companies. Continuous investment in single-use technologies and high-containment facilities is supporting this shift. As a result, service portfolios are becoming more specialized and innovation-oriented.
Rising Strategic Partnerships and Long-Term Contracts
Pharmaceutical and biotechnology companies are entering long-term collaborations with CDMOs to secure reliable capacity and technical continuity. These partnerships extend beyond manufacturing to include early-stage development, analytical services, and lifecycle management. The approach reduces operational risk while improving cost predictability and speed of execution. European CDMOs are responding by offering integrated, end-to-end service models. This trend is strengthening client retention and stabilizing revenue streams across the market.
Market Segmentation
Contract development services are gaining momentum as pharmaceutical and biotechnology firms prioritize faster formulation design and early-stage process optimization. Growth is supported by the rising number of small and mid-size biotech’s that lack in-house development infrastructure. Leading European providers are expanding capabilities in analytical testing, biologics development, and regulatory support. Recent activity shows increased investment in digital modelling and quality-by-design approaches. Clients are seeking development partners that can reduce technical risk before commercialization. This shift is reinforcing the strategic importance of development-focused CDMOs.
Contract Manufacturing: A Key Segment in Market Growth
Contract manufacturing continues to dominate demand as companies aim to manage costs while ensuring reliable large-scale production. Growth is driven by the outsourcing of complex dosage forms, sterile injectables, and biologics manufacturing. Established European manufacturers with strong compliance records and flexible capacity remain preferred partners. Recent trends include facility expansions, adoption of continuous manufacturing, and increased use of single-use systems. These developments are enabling faster scale-up and improved supply security.
Regional Outlook
The European CDMO market is further divided by countries, including the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe.
Germany Dominates the Market with a Major Share
Germany represents one of the most developed CDMO markets in Europe, supported by a strong pharmaceutical manufacturing base and advanced research infrastructure. The country benefits from a high concentration of global and regional CDMOs with expertise in both small molecules and biologics. Growth is driven by sustained investment in innovation, particularly in biologics, biosimilars, and high-potency active ingredients. A well-established regulatory environment and skilled workforce enhance Germany’s attractiveness as an outsourcing destination. Recent trends include capacity expansion, modernization of manufacturing facilities, and increased collaboration with emerging biotechnology firms.
Market Players Outlook
The major companies operating in the European CDMO market include Lonza Group AG, Thermo Fisher Scientific Inc., WuXi Biologics Co., Ltd., Siegfried Holding AG, and Eurofins Scientific SE, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
Industry Overview
European CDMO market was valued at $45.6 billion in 2025 and is projected to reach $73.1 billion by 2035, growing at a CAGR of 4.9% during the forecast period (2026–2035). The European healthcare contract development and manufacturing organization market is expanding steadily, supported by rising demand for specialized pharmaceutical outsourcing and advanced biologics production. Increased investment in research-intensive therapies has encouraged pharmaceutical companies to rely on external partners with niche technical expertise. Regulatory harmonization across the region has improved cross-border manufacturing efficiency and reduced time-to-market. Growth is further reinforced by the expansion of small and mid-sized biotech firms seeking flexible development and scale-up capabilities. Technological upgrades in process automation and quality control have strengthened operational reliability. Together, these factors continue to support sustained market expansion over the forecast period.
Market Dynamics
Expansion of Biologics and Advanced Therapies
European CDMOs are increasingly focusing on biologics, cell, and gene therapies, and complex injectables as pharmaceutical pipelines shift toward high-value, specialized treatments. This trend is driven by the need for sophisticated development capabilities, regulatory expertise, and scalable manufacturing infrastructure. Contract manufacturers with proven experience in biologics are gaining preference among innovator companies. Continuous investment in single-use technologies and high-containment facilities is supporting this shift. As a result, service portfolios are becoming more specialized and innovation-oriented.
Rising Strategic Partnerships and Long-Term Contracts
Pharmaceutical and biotechnology companies are entering long-term collaborations with CDMOs to secure reliable capacity and technical continuity. These partnerships extend beyond manufacturing to include early-stage development, analytical services, and lifecycle management. The approach reduces operational risk while improving cost predictability and speed of execution. European CDMOs are responding by offering integrated, end-to-end service models. This trend is strengthening client retention and stabilizing revenue streams across the market.
Market Segmentation
- Based on the services, the market is segmented into contract development and contract manufacturing.
Contract development services are gaining momentum as pharmaceutical and biotechnology firms prioritize faster formulation design and early-stage process optimization. Growth is supported by the rising number of small and mid-size biotech’s that lack in-house development infrastructure. Leading European providers are expanding capabilities in analytical testing, biologics development, and regulatory support. Recent activity shows increased investment in digital modelling and quality-by-design approaches. Clients are seeking development partners that can reduce technical risk before commercialization. This shift is reinforcing the strategic importance of development-focused CDMOs.
Contract Manufacturing: A Key Segment in Market Growth
Contract manufacturing continues to dominate demand as companies aim to manage costs while ensuring reliable large-scale production. Growth is driven by the outsourcing of complex dosage forms, sterile injectables, and biologics manufacturing. Established European manufacturers with strong compliance records and flexible capacity remain preferred partners. Recent trends include facility expansions, adoption of continuous manufacturing, and increased use of single-use systems. These developments are enabling faster scale-up and improved supply security.
Regional Outlook
The European CDMO market is further divided by countries, including the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe.
Germany Dominates the Market with a Major Share
Germany represents one of the most developed CDMO markets in Europe, supported by a strong pharmaceutical manufacturing base and advanced research infrastructure. The country benefits from a high concentration of global and regional CDMOs with expertise in both small molecules and biologics. Growth is driven by sustained investment in innovation, particularly in biologics, biosimilars, and high-potency active ingredients. A well-established regulatory environment and skilled workforce enhance Germany’s attractiveness as an outsourcing destination. Recent trends include capacity expansion, modernization of manufacturing facilities, and increased collaboration with emerging biotechnology firms.
Market Players Outlook
The major companies operating in the European CDMO market include Lonza Group AG, Thermo Fisher Scientific Inc., WuXi Biologics Co., Ltd., Siegfried Holding AG, and Eurofins Scientific SE, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In April 2025, Meribel Pharma Solutions launched operations across Europe. The company enters the market with ten manufacturing sites and three drug development service locations spread across France, Spain, and Sweden. The launch follows the acquisition of the Synerlab Group and seven European manufacturing facilities from Recipharm in 2023. Meribel Pharma Solutions is now positioned as a pan-European CDMO serving customers with capabilities across the drug development and manufacturing lifecycle.
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the European CDMO market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
Table of Contents
104 Pages
- 1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- European CDMO Market Sales Analysis – Services ($ Million)
- European CDMO Market Sales Performance of Top Countries
- 1.1. Research Methodology
- Primary Research Approach
- Secondary Research Approach
- 1.2. Market Snapshot
- 2. Market Overview and Insights
- 2.1. Scope of the Study
- 2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key European CDMO Industry Trends
- 2.2.2. Market Recommendations
- 3. Market Determinants
- 3.1. Market Drivers
- 3.1.1. Drivers For European CDMO Market: Impact Analysis
- 3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For European CDMO Market: Impact Analysis
- 3.3. Market Opportunities
- 3.3.1. Opportunities For European CDMO Market: Impact Analysis
- 4. Competitive Landscape
- 4.1. Competitive Dashboard – European CDMO Market Revenue and Share by Manufacturers
- CDMO Product Comparison Analysis
- Top Market Player Ranking Matrix
- 4.2. Key Company Analysis
- 4.2.1. Eurofins Scientific SE
- 4.2.1.1. Overview
- 4.2.1.2. Product Portfolio
- 4.2.1.3. Financial Analysis
- 4.2.1.4. SWOT Analysis
- 4.2.1.5. Business Strategy
- 4.2.2. Lonza Group AG
- 4.2.2.1. Overview
- 4.2.2.2. Product Portfolio
- 4.2.2.3. Financial Analysis
- 4.2.2.4. SWOT Analysis
- 4.2.2.5. Business Strategy
- 4.2.3. Siegfried Holding AG
- 4.2.3.1. Overview
- 4.2.3.2. Product Portfolio
- 4.2.3.3. Financial Analysis
- 4.2.3.4. SWOT Analysis
- 4.2.3.5. Business Strategy
- 4.2.4. Thermo Fisher Scientific Inc.
- 4.2.4.1. Overview
- 4.2.4.2. Product Portfolio
- 4.2.4.3. Financial Analysis
- 4.2.4.4. SWOT Analysis
- 4.2.4.5. Business Strategy
- 4.2.5. WuXi Biologics Co., Ltd.
- 4.2.5.1. Overview
- 4.2.5.2. Product Portfolio
- 4.2.5.3. Financial Analysis
- 4.2.5.4. SWOT Analysis
- 4.2.5.5. Business Strategy
- 4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration
- 5. European CDMO Market Sales Analysis by Services ($ Million)
- 5.1. Contract Development
- 5.2. Contract Manufacturing
- 6. Regional Analysis
- 6.1. European CDMO Market Sales Analysis – Services Country ($ Million)
- Macroeconomic Factors for European
- 6.1.1. UK
- 6.1.2. Germany
- 6.1.3. Italy
- 6.1.4. Spain
- 6.1.5. France
- 6.1.6. Russia
- 6.1.7. Rest of Europe
- 7. Company Profiles
- 7.1. AGC Biologics Inc.
- 7.1.1. Quick Facts
- 7.1.2. Company Overview
- 7.1.3. Product Portfolio
- 7.1.4. Business Strategies
- 7.2. Aenova Group GmbH
- 7.2.1. Quick Facts
- 7.2.2. Company Overview
- 7.2.3. Product Portfolio
- 7.2.4. Business Strategies
- 7.3. Boehringer Ingelheim International GmbH
- 7.3.1. Quick Facts
- 7.3.2. Company Overview
- 7.3.3. Product Portfolio
- 7.3.4. Business Strategies
- 7.4. Cambrex Corp.
- 7.4.1. Quick Facts
- 7.4.2. Company Overview
- 7.4.3. Product Portfolio
- 7.4.4. Business Strategies
- 7.5. Catalent, Inc.
- 7.5.1. Quick Facts
- 7.5.2. Company Overview
- 7.5.3. Product Portfolio
- 7.5.4. Business Strategies
- 7.6. Eurofins Scientific SE
- 7.6.1. Quick Facts
- 7.6.2. Company Overview
- 7.6.3. Product Portfolio
- 7.6.4. Business Strategies
- 7.7. Fareva S.A.S.
- 7.7.1. Quick Facts
- 7.7.2. Company Overview
- 7.7.3. Product Portfolio
- 7.7.4. Business Strategies
- 7.8. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
- 7.8.1. Quick Facts
- 7.8.2. Company Overview
- 7.8.3. Product Portfolio
- 7.8.4. Business Strategies
- 7.9. Jubilant Biosys Ltd.
- 7.9.1. Quick Facts
- 7.9.2. Company Overview
- 7.9.3. Product Portfolio
- 7.9.4. Business Strategies
- 7.10. KBI Biopharma, Inc.
- 7.10.1. Quick Facts
- 7.10.2. Company Overview
- 7.10.3. Product Portfolio
- 7.10.4. Business Strategies
- 7.11. Lonza Group AG
- 7.11.1. Quick Facts
- 7.11.2. Company Overview
- 7.11.3. Product Portfolio
- 7.11.4. Business Strategies
- 7.12. Neuland Laboratories Ltd.
- 7.12.1. Quick Facts
- 7.12.2. Company Overview
- 7.12.3. Product Portfolio
- 7.12.4. Business Strategies
- 7.13. Pharmaron (Beijing) Co., Ltd.
- 7.13.1. Quick Facts
- 7.13.2. Company Overview
- 7.13.3. Product Portfolio
- 7.13.4. Business Strategies
- 7.14. Piramal Pharma Ltd.
- 7.14.1. Quick Facts
- 7.14.2. Company Overview
- 7.14.3. Product Portfolio
- 7.14.4. Business Strategies
- 7.15. Recipharm AB
- 7.15.1. Quick Facts
- 7.15.2. Company Overview
- 7.15.3. Product Portfolio
- 7.15.4. Business Strategies
- 7.16. Siegfried Holding AG
- 7.16.1. Quick Facts
- 7.16.2. Company Overview
- 7.16.3. Product Portfolio
- 7.16.4. Business Strategies
- 7.17. Thermo Fisher Scientific Inc.
- 7.17.1. Quick Facts
- 7.17.2. Company Overview
- 7.17.3. Product Portfolio
- 7.17.4. Business Strategies
- 7.18. WuXi AppTec Co., Ltd.
- 7.18.1. Quick Facts
- 7.18.2. Company Overview
- 7.18.3. Product Portfolio
- 7.18.4. Business Strategies
- 7.19. WuXi Biologics Co., Ltd.
- 7.19.1. Quick Facts
- 7.19.2. Company Overview
- 7.19.3. Product Portfolio
- 7.19.4. Business Strategies
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
